NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-23
Reading NVO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Primary pillar under pressure — EPS at or above $21.6 in FY26: metric not reported.
View ThesisThis stock is volatile — it swings about 1% on a typical day and fell roughly 49% in its worst 12-month stretch.
View RiskNovo Nordisk's growth depends on the success of its Wegovy products. Recent approvals for Wegovy in India and the EU enhance its market potential. The stock trades at a premium compared to peers, which raises concerns about sustainability. If major competitors like Eli Lilly start winning lawsuits, it could hurt Novo Nordisk. Peer multiples imply a price about 16% below where it trades. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Trailing returns as of 2026-07-24. NVO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering NVO (as of Jul 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-07-24. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Blocking competitor ads strengthens market position.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-24. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Lawsuit impacts competitive landscape and market perception.
Legal action may enhance brand protection and market position.
Oral Wegovy's momentum supports growth expectations.
Wegovy's approval expands market potential significantly.
First EU approval enhances product portfolio and market potential.
Positive development in product pipeline enhances growth prospects.
Emerging growth conference highlights positive momentum for implant.
